Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

By Moorthy V.S.   McConkey S.   Roberts M.   Gothard P.   Arulanantham N.   Degano P.   Schneider J.   Hannan C.   Roy M.   Gilbert S.C.   Peto T.E.A.   Hill A.V.S.  

Vaccine, Vol. 21, Iss. 17, 2003-05 ,pp. : 2004-2011

Elsevier

Access to resources Recommend Favorite

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model

By Carroll M.W.   Overwijk W.W.   Chamberlain R.S.   Rosenberg S.A.   Moss B.   Restifo N.P.  

Vaccine, Vol. 15, Iss. 4, 1997-03 ,pp. : 387-394

Elsevier

Access to resources Recommend Favorite

Enhanced CD8 + T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector

By Gomez C.E.   Rodrguez D.   Rodrguez J.R.   Abaitua F.   Duarte C.   Esteban M.  

Vaccine, Vol. 20, Iss. 5, 2001-12 ,pp. : 961-971

Elsevier

Access to resources Recommend Favorite

Virus-like particle and DNA-based candidate AIDS vaccines

By Yao Q.   Bu Z.   Vzorov A.   Yang C.   Compans R.W.  

Vaccine, Vol. 21, Iss. 7, 2003-01 ,pp. : 638-643

Elsevier

Access to resources Recommend Favorite

Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

By Huemer H.P.   Strobl B.   Nowotny N.  

Vaccine, Vol. 18, Iss. 14, 2000-02 ,pp. : 1320-1326

Elsevier

Access to resources Recommend Favorite